Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms
Effects of Individualized Resting-State fMRI-Guided Intermittent Theta-Burst Stimulation on Depressive and Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome: A Randomized, Double-Blind, Sham-Controlled Trial
This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.
A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).
Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).
An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jie Li
- 電話番号:+8615988858667
- メール:jie_sweethz@163.com
研究場所
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310015
- 募集
- The Affiliated Hospital of Hangzhou Normal University
-
コンタクト:
- Jie Li
- 電話番号:+8615988858667
- メール:jie_sweethz@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Right-handed individuals.
- Diagnosis of irritable bowel syndrome according to the Rome IV criteria.
- Presence of depressive symptoms, defined as a HAMD-17 score greater than 7.
- Inadequate response to at least two months of conventional treatment for IBS.
- Ability to understand the study procedures and provide written informed consent.
- Willingness and ability to undergo MRI examinations and complete the study assessments.
Exclusion Criteria:
- Contraindications to MRI or transcranial magnetic stimulation.
- Known food intolerance, relevant gastrointestinal surgery, or gastrointestinal diseases other than IBS that may explain the symptoms.
- History of significant neurological disorders or psychiatric disorders other than the depressive symptoms under investigation.
- History of intracranial surgery.
- Intracranial mass lesions or severe white matter abnormalities detected by MRI.
- Other conditions that, in the investigator's judgment, would make participation inappropriate or unsafe.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Active Individualized iTBS
Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis. Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions. |
Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks. |
|
偽コンパレータ:Sham iTBS
Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation. Participants will receive five sessions per week for two weeks, for a total of 10 sessions. |
A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2
時間枠:Baseline and end of Week 2
|
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups. |
Baseline and end of Week 2
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in IBS Symptom Severity at Week 2
時間枠:Baseline and end of Week 2
|
IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups. |
Baseline and end of Week 2
|
|
Change From Baseline in Abdominal Pain Intensity at Week 2
時間枠:Baseline and end of Week 2
|
Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS). |
Baseline and end of Week 2
|
|
Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2
時間枠:Baseline and end of Week 2
|
Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ). |
Baseline and end of Week 2
|
|
Change From Baseline in Anxiety Symptom Severity at Week 2
時間枠:Baseline and end of Week 2
|
Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). |
Baseline and end of Week 2
|
|
Change From Baseline in IBS-Related Quality of Life at Week 2
時間枠:Baseline and end of Week 2
|
IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL). |
Baseline and end of Week 2
|
|
MRI Outcomes
時間枠:Baseline and end of Week 2
|
functional and structural brain network analyses |
Baseline and end of Week 2
|
|
Safety Outcomes
時間枠:Baseline and end of Week 2
|
adverse-event incidence |
Baseline and end of Week 2
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。